191 related articles for article (PubMed ID: 22080966)
1. HLA-matched sibling stem cell transplantation in children with β-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience.
Goussetis E; Peristeri I; Kitra V; Vessalas G; Paisiou A; Theodosaki M; Petrakou E; Dimopoulou MN; Graphakos S
Bone Marrow Transplant; 2012 Aug; 47(8):1061-6. PubMed ID: 22080966
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
3. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
4. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
[TBL] [Abstract][Full Text] [Related]
6. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.
Hussein AA; Al-Zaben A; Ghatasheh L; Natsheh A; Hammada T; Abdel-Rahman F; Abu-Jazar H; Sharma S; Najjar R; Frangoul H
Pediatr Blood Cancer; 2013 Aug; 60(8):1345-9. PubMed ID: 23424175
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
[TBL] [Abstract][Full Text] [Related]
8. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group.
La Nasa G; Argiolu F; Giardini C; Pession A; Fagioli F; Caocci G; Vacca A; De Stefano P; Piras E; Ledda A; Piroddi A; Littera R; Nesci S; Locatelli F
Ann N Y Acad Sci; 2005; 1054():186-95. PubMed ID: 16339665
[TBL] [Abstract][Full Text] [Related]
9. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N; Zabelina T; Binder T; Ayuk F; Bacher U; Amtsfeld G; Lellek H; Schrum J; Erttmann R; Eiermann T; Zander A
Biol Blood Marrow Transplant; 2009 Apr; 15(4):454-62. PubMed ID: 19285633
[TBL] [Abstract][Full Text] [Related]
10. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
[TBL] [Abstract][Full Text] [Related]
11. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation for severe aplastic anemia: graft rejection remains a problem.
Aki SZ; Sucak GT; Ozkurt ZN; Yeğin ZA; Yağci M; Haznedar R
Transfus Apher Sci; 2009 Feb; 40(1):5-11. PubMed ID: 19121979
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
14. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
15. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
16. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions.
Galambrun C; Pondarré C; Bertrand Y; Loundou A; Bordigoni P; Frange P; Lutz P; Mialou V; Rubie H; Socié G; Schneider P; Bernaudin F; Paillard C; Michel G; Badens C; Thuret I; ;
Biol Blood Marrow Transplant; 2013 Jan; 19(1):62-8. PubMed ID: 22892550
[TBL] [Abstract][Full Text] [Related]
17. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
[TBL] [Abstract][Full Text] [Related]
18. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
19. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
Resnick IB; Aker M; Tsirigotis P; Shapira MY; Abdul-Hai A; Bitan M; Gesundheit B; Amar A; Ackerstein A; Samuel S; Slavin S; Or R
Bone Marrow Transplant; 2007 Nov; 40(10):957-64. PubMed ID: 17846604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
